Sulfamethoxazole
FDA-approved product (tablet, oral), marketed as Gantanol, Gantanol-Ds, Sulfamethoxazole and 1 more.
- Registered studies
- 50+
- Lab records
- 17
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
- Pneumocystosis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Intermediate-acting sulfonamides
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01EC01
Repurposing investigation
Sulfamethoxazole is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- K. pneumoniae: measured active in 0 of 17 lab records
Show the 17 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sulfamethoxazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS
NCT00000715
Registered record
- Registry ID
- NCT00000715
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Pentamidine isethionate; Sulfamethoxazole-Trimethoprim
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1991-09
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionPentamidine isethionate; Sulfamethoxazole-TrimethoprimPhasePhase 3Registry statusCompletedComparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
NCT00000730
Registered record
- Registry ID
- NCT00000730
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Trimetrexate glucuronate; Methylprednisolone; Pentamidine isethionate; Sulfamethoxazole-Trimethoprim; Leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- Not recorded
- Completion
- 1989-03
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionTrimetrexate glucuronate; Methylprednisolone; Pentamidine isethionate; Sulfamethoxazole-Trimethoprim +1 morePhasePhase 3Registry statusTerminatedEvaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine
NCT00000732
Registered record
- Registry ID
- NCT00000732
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1990-05
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionSulfamethoxazole-Trimethoprim; ZidovudinePhaseNot applicableRegistry statusCompletedEvaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
NCT00000734
Registered record
- Registry ID
- NCT00000734
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1990-05
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionSulfamethoxazole-Trimethoprim; ZidovudinePhaseNot applicableRegistry statusCompletedA Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole
NCT00001027
Registered record
- Registry ID
- NCT00001027
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Pentamidine isethionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1996-09
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionPentamidine isethionatePhasePhase 1Registry statusCompleted